|
Impact of SPARC expression level on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: A pooled analysis from prospective clinical and translational trials. |
|
|
|
Consulting or Advisory Role - Labceutics |
|
|
Consulting or Advisory Role - Celgene |
Research Funding - Boston Biomedical (Inst); Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Boston Biomedical; Celgene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Roche Pharma AG; Vifor Pharma |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Boston Scientific; Cook Medical |
|
|
Travel, Accommodations, Expenses - Celgene |
|
|
No Relationships to Disclose |
|
|
Honoraria - Boehringer Ingelheim; Celgene; Roche Pharma AG |
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Roche Pharma AG |
Research Funding - Boehringer Ingelheim (Inst); Celgene (Inst); Roche Pharma AG (Inst) |
|
|
Honoraria - Celgene; Roche Pharma AG |
Consulting or Advisory Role - Celgene |
Research Funding - Celgene (Inst) |
Travel, Accommodations, Expenses - Celgene |